In the field of influenza treatment, Sebaloxavir Marbaxil Tablets (trade name: Jikeshu), independently developed in China, marks a significant technological breakthrough, providing a new solution for global public health. As an innovative drug, it was approved for marketing by the National Medical Products Administration in July 2025. Specifically designed for adults with uncomplicated influenza A and B, it redefines treatment standards with the concept of "one dose for relief."

Core Technology: A "Molecular Scalpel" Targeting Viral Replication

Sebaloxavir Marbaxil Tablets is the world's first anti-influenza drug containing selenium atoms. Its innovation stems from the specific inhibition of the PA subunit of viral RNA polymerase. Traditional drugs often act on the viral surface or during the release phase, while this drug directly intervenes in the core process of viral genome replication—mRNA transcription—blocking viral replication at its source. This mechanism endows it with sustained antiviral activity; a single oral dose can maintain an effective blood concentration, achieving rapid efficacy with "fever reduction within one day."

Clinical Advantages: A Dual Revolution in Speed ​​and Safety

Phase III clinical trials showed that the median time to symptom relief was only 39.4 hours, and the time to viral clearance was shortened to 41.4 hours, significantly better than the placebo group. Its long-lasting effect stems from its linear pharmacokinetic characteristics, long half-life, and high plasma exposure level, supporting a single-dose regimen for the entire treatment course. In terms of safety, the incidence of adverse reactions was as low as 0.3%, and it is not dependent on CYP450 enzyme metabolism, significantly reducing the risk of drug interactions. The study was led by authoritative experts such as Zhang Wenhong and Zhu Huadong, and the results were published in top international journals, verifying its high suitability for Chinese patients.

Application Prospects: From Laboratory to Global Health

Currently, the drug is available in 19 provinces and cities, exclusively promoted by Jichuan Pharmaceutical, and is well-suited to the physical characteristics of Chinese patients. Future clinical trials expanding to adolescents and children are underway, potentially covering a wider population. As a benchmark for China's anti-influenza program, it not only breaks the monopoly of imported drugs but also helps patients quickly return to a healthy life with its convenient "one-dose, long-lasting, and safe" approach.

The creation of Sebaloxavir Marbaxil Tablets demonstrates China's leading position in antiviral drug research and development, contributing "Chinese wisdom" to global influenza prevention and control.